DNA hypermethylation of the ZNF132 gene participates in the clinicopathological aggressiveness of ‘pan-negative’-type lung adenocarcinomas

Abstract Although some previous studies have examined epigenomic alterations in lung adenocarcinomas, correlations between epigenomic events and genomic driver mutations have not been fully elucidated. Single-CpG resolution genome-wide DNA methylation analysis with the Infinium HumanMethylation27 BeadChip was performed using 162 paired samples of adjacent normal lung tissue (N) and the corresponding tumorous tissue (T) from patients with lung adenocarcinomas. Correlations between DNA methylation data on the one hand and clinicopathological parameters and genomic driver mutations, i.e. mutations of EGFR, KRAS, BRAF and HER2 and fusions involving ALK, RET and ROS1, were examined. DNA methylation levels in 12 629 probes from N samples were significantly correlated with recurrence-free survival. Principal component analysis revealed that distinct DNA methylation profiles at the precancerous N stage tended not to induce specific genomic driver aberrations. Most of the genes showing significant DNA methylation alterations during transition from N to T were shared by two or more driver aberration groups. After small interfering RNA knockdown of ZNF132, which showed DNA hypermethylation only in the pan-negative group and was correlated with vascular invasion, the proliferation, apoptosis and migration of cancer cell lines were examined. ZNF132 knockdown led to increased cell migration ability, rather than increased cell growth or reduced apoptosis. We concluded that DNA hypermethylation of the ZNF132 gene participates in the clinicopathological aggressiveness of ‘pan-negative’ lung adenocarcinomas. In addition, DNA methylation alterations at the precancerous stage may determine tumor aggressiveness, and such alterations that accumulate after driver mutation may additionally modify clinicopathological features through alterations of gene expression.

[1]  Teruhiko Yoshida,et al.  Establishment of diagnostic criteria for upper urinary tract urothelial carcinoma based on genome-wide DNA methylation analysis , 2020, Epigenetics.

[2]  P. Padma,et al.  Epigenetic alterations in cancer. , 2020, Frontiers in bioscience.

[3]  H. Popper,et al.  Adenocarcinoma , 2020, Essentials of Diagnostic Pathology.

[4]  Y. Kanai,et al.  Genome-wide DNA methylation profile of early-onset endometrial cancer: its correlation with genetic aberrations and comparison with late-onset endometrial cancer , 2019, Carcinogenesis.

[5]  M. Noguchi,et al.  DNA hypomethylation-related overexpression of SFN, GORASP2 and ZYG11A is a novel prognostic biomarker for early stage lung adenocarcinoma , 2019, Oncotarget.

[6]  V. Cardaci,et al.  Tobacco Smoking: Risk to Develop Addiction, Chronic Obstructive Pulmonary Disease, and Lung Cancer. , 2019, Recent patents on anti-cancer drug discovery.

[7]  Shicheng Guo,et al.  Epigenetic silencing of ZNF132 mediated by methylation-sensitive Sp1 binding promotes cancer progression in esophageal squamous cell carcinoma , 2018, Cell Death & Disease.

[8]  Y. Totoki,et al.  Epigenome mapping of human normal purified hepatocytes: personal epigenome variation and genome-epigenome correlation. , 2018, Epigenomics.

[9]  R. Fry,et al.  Environmental Influences on the Epigenome: Exposure- Associated DNA Methylation in Human Populations. , 2018, Annual review of public health.

[10]  Y. Miyagi,et al.  The Japanese Society of Pathology Guidelines on the handling of pathological tissue samples for genomic research: Standard operating procedures based on empirical analyses , 2018, Pathology international.

[11]  T. Graham,et al.  An evolutionary perspective on field cancerization , 2017, Nature Reviews Cancer.

[12]  I. Wistuba,et al.  DNA methylation intratumor heterogeneity in localized lung adenocarcinomas , 2017, Oncotarget.

[13]  Y. Kanai,et al.  Genome-wide DNA methylation analysis during non-alcoholic steatohepatitis-related multistage hepatocarcinogenesis: comparison with hepatitis virus-related carcinogenesis , 2017, Carcinogenesis.

[14]  T. Kohno,et al.  Genes involved in development and differentiation are commonly methylated in cancers derived from multiple organs: a single-institutional methylome analysis using 1007 tissue specimens , 2016, Carcinogenesis.

[15]  T. Kohno,et al.  Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy , 2017, Surgery Today.

[16]  Peter A. Jones,et al.  Targeting the cancer epigenome for therapy , 2016, Nature Reviews Genetics.

[17]  Peter A. Jones,et al.  Epigenetic Determinants of Cancer. , 2016, Cold Spring Harbor perspectives in biology.

[18]  Vessela Kristensen,et al.  Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis , 2015, Molecular oncology.

[19]  尾原 健太郎 Genes involved in development and differentiation are commonly methylated in cancers derived from multiple organs : a single-institutional methylome analysis using 1007 tissue specimens(審査報告) , 2016 .

[20]  David Petersen,et al.  An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Teruhiko Yoshida,et al.  Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas , 2015, International journal of cancer.

[22]  Takanori Kanai,et al.  Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids , 2015, Nature Medicine.

[23]  Teruhiko Yoshida,et al.  Epigenetic clustering of gastric carcinomas based on DNA methylation profiles at the precancerous stage: its correlation with tumor aggressiveness and patient outcome , 2014, Carcinogenesis.

[24]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[25]  Y. Kanai,et al.  Multilayer-omics analyses of human cancers: exploration of biomarkers and drug targets based on the activities of the International Human Epigenome Consortium , 2014, Front. Genet..

[26]  T. Betsuyaku,et al.  Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease , 2013, International journal of cancer.

[27]  Koji Tsuta,et al.  DNA Methylation Profiles at Precancerous Stages Associated with Recurrence of Lung Adenocarcinoma , 2013, PloS one.

[28]  Y. Kanai,et al.  Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas , 2012, Carcinogenesis.

[29]  K. D. Sørensen,et al.  Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis , 2012, International journal of cancer.

[30]  Xiao Zhang,et al.  Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis , 2010, BMC Bioinformatics.

[31]  K. Gunderson,et al.  Genome-wide DNA methylation profiling using Infinium® assay. , 2009, Epigenomics.

[32]  C. Ambrosone,et al.  Molecular epidemiology to better predict lung cancer risk. , 2008, Clinical lung cancer.

[33]  B. Reiser,et al.  Estimation of the Youden Index and its Associated Cutoff Point , 2005, Biometrical journal. Biometrische Zeitschrift.

[34]  S. Hirohashi,et al.  DNA hypermethylation at the D17S5 locus in non-small cell lung cancers: its association with smoking history. , 1997, Cancer research.

[35]  J. Minna,et al.  NCI‐navy medical oncology branch cell line data base , 1996, Journal of cellular biochemistry. Supplement.

[36]  K. Fujise,et al.  Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines. , 1990, Hepato-gastroenterology.

[37]  K. Tanaka,et al.  Thromboplastic and fibrinolytic activities of cultured human cancer cell lines. , 1979, British Journal of Cancer.

[38]  S. Aaronson,et al.  In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. , 1973, Journal of the National Cancer Institute.